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Several lines of evidence have shown the association of latent
Epstein–Barr virus (EBV) infection with the nasal-type, extra-
nodal natural killer or T (NK/T)-cell lymphoma which occurs
predominantly in Asia and Mexico (Harabuchi et al, 1990; Su 
et al, 1991; Jaffe et al, 1996; Harris et al, 1999). This type of
lymphoma primarily affects the nasal cavity and skin, exhibiting
histopathological features of angiodestructive infiltration and
tissue necrosis (Su and Hsieh, 1992; Jaffe et al, 1996; Chan et al,
1997; Iwatsuki et al, 1997), and a frequent complication of
haemophagocytic syndrome (Jaffe et al, 1983, 1996). In addition
to the presence of EBV-DNA, EBV-encoded nuclear RNA
(EBER) is usually present in the neoplastic cells. The detection of
these molecules, therefore, provides a diagnostic clue for this
disorder. Although viral proteins such as latent membrane protein
(LMP) and EBV nuclear antigen (EBNA) may have a crucial role
for EBV-induced cell transformation (Wang et al, 1985; Rickinson
et al, 1987), the in vivo expression pattern of the virus-related
molecules has not yet been clarified in the nasal type, NK/T-cell
lymphoma. 
EBV-infected cells and neoplasms generally show one of three
different patterns of latency-associated viral gene expression:
latency I, II and III (Rowe et al, 1987; Kerr et al, 1992). EBV-
infected lymphoblastoid cell lines and lymphoproliferative
diseases arising in immunocompromised hosts express all nine
latency-associated viral proteins, including six EBNAs (1, 2, 3A,
3B, 3C and LP) and three LMPs (1, 2A and 2B) (Rowe et al, 1987;
Young et al, 1989; Hamilton-Dutoit et al, 1993). This pattern of
EBV gene expression is designated as latency III. 
In latency II, as noted in EBV-associated Hodgkin’s disease
and nasopharyngeal carcinoma, the EBNA-1, LMP-1 and LMP-2
genes but not other EBNA genes are transcribed (Brooks et al,
1992; Deacon et al, 1993). In latency I, EBV-infected cells express
only EBNA-1, which is essential for episomal replication. This
pattern is found in Burkitt’s lymphomas (Tao et al, 1998) and
gastric carcinomas (Sugiura et al, 1996). 
The differences in the three patterns of EBV gene transcription
are determined by cell phenotypes and the usage of gene promoters.
The EBNA genes are transcribed as a single polycistronic RNA
molecule which is spliced to give rise to expression of the individual
EBNA molecules. The transcription in latency III is initiated from a
promoter, located within the BamHI regions C and W (the C/W
promoter, Cp/Wp) and results in a Y/U/K-spliced EBNA1 mRNA,
whereas transcription of only EBNA-1 in latency I is driven by a
downstream promoter located in the BamHI F and Q regions (the Q
promoter, Qp), generating a Q/U/K-spliced mRNA without other
EBNA products (Sample et al, 1991; Schaefer et al, 1991). 
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Summary The nasal type, extranodal natural killer or T(NK/T)-cell lymphoma is usually associated with latent Epstein–Barr virus (EBV)
infection. In order to elucidate the EBV gene expression patterns in vivo, we examined eight patients with cutaneous EBV-related NK/T-cell
lymphomas, including six patients with a NK-cell phenotype and two patients with a T-cell phenotype. The implication of EBV in the skin
lesions was determined by the presence of EBV-DNA, EBV-encoded nuclear RNA (EBER) and a clonality of EBV-DNA fragments containing
the terminal repeats. Transcripts of EBV-encoded genes were screened by reverse transcription- polymerase chain reaction (RT-PCR), and
confirmed by Southern blot hybridization. The expression of EBV-related antigens was examined by immunostaining using paraffin-
embedded tissue sections and cell pellets of EBV-positive cell lines. Our study demonstrated that all samples from the patients contained
EBV nuclear antigen (EBNA)-1 mRNA which was transcribed using the Q promoter, whereas both the Q promoter and another upstream
promoter (Cp/Wp) were used in EBV-positive cell lines, B95.8, Raji and Jiyoye. Latent membrane protein-1 (LMP-1) mRNA was detected in
seven of eight patients and all cell lines, whereas EBNA-2 transcripts were found only in the cell lines. Immunostaining showed no LMP-1,
EBNA-2 or ZEBRA antigens in the paraffin-embedded tissue sections, although they were positive in the cell line cells. Latent BHRF1
transcripts encoding bcl-2 homologue and BCRF1 transcripts encoding viral interleukin (vIL)-10 were detected in one and two of eight
patients, respectively. A patient with NK-cell lymphoma expressing both transcripts died of rapid progression of the illness. Our results
indicate that the restricted expression of the latency-associated EBV genes and the production of vIL-10 and bcl-2 homologue may favour
tumour growth, evading the host immune surveillance. © 2001 Cancer Research Campaign http://www.bjcancer.com
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proteins that modulate the host’s immune system and inhibit
apoptosis. The BHRF1 gene has partial sequence homology to 
the human bcl-2 gene (Henderson et al, 1993) and the BCRF1 gene
encodes viral interleukin (IL)-10 (Moore et al, 1990).
Furthermore, the BARF1-encoded protein functions as a soluble
receptor for colony-stimulating factor 1 which inhibits interferon-a
secretion from mononuclear cells (Cohen et al, 1999). The expres-
sion of these molecules may be implicated in the outgrowth of
EBV-infected cells. 
In order to clarify the latency pattern and the expression of
EBV-encoded immunoregulatory molecules, we examined the
biopsy specimens from eight Japanese patients with EBV-related
cutaneous NK/T-cell lymphomas. We investigated transcripts of
latency-associated EBV genes, the BHRF1 (bcl-2 homologue) and
the BCRF1 (viral IL-10) genes in tumour tissues by reverse-
transcription polymerase chain reaction (RT-PCR) and Southern
blot hybridization. 
PATIENTS, MATERIALS AND METHODS 
Patients 
Eight patients with nasal-type, extranodal NK/T-cell lymphoma
including six patients with a NK-cell phenotype and two with a 
T-cell phenotype were enrolled in the study. The diagnoses were
confirmed by immunophenotyping of the infiltrating cells and the
detection of EBV-DNA, EBV-encoded RNA (EBER) and a
clonality of EBV-DNA fragment containing the terminal repeat as
described below. The clinical manifestations of two patients (NK3
and T1) have been reported in detail elsewhere (Ohtsuka et al,
1999). 
Tumour samples and cell lines 
Paraffin-embedded skin biopsy specimens from the eight patients
were examined for immunophenotypes, EBER and EBV antigens,
including LMP-1, EBNA2 and ZEBRA. DNA samples from
frozen skin biopsies were used for clonality analyses of T-cell
receptor gene rearrangement and EBV terminal repeats, and for
the determination of EBV gene transcripts. Two established EBV-
positive Burkitt’s lymphoma cell lines, Raji and Jiyoye, and one
EBV-transformed lymphoblastoid cell line, B95.8, served as posi-
tive controls for EBV gene transcription. An EBV-negative T-cell
line, Molt, was used as a negative control for RT-PCR. All cell
lines were cultured in RPMI 1640 supplemented with 10%
fetal bovine serum, 1 mM glutamine, 100 U/ml–1 penicillin and
1 0 0Um l –1 streptomycin. 
In situ hybridization for EBER 
In situ hybridization was performed on paraffin-embedded
sections. After deparaffinization and digestion with 0.8% pepsin
(DAKO, Glostrup), the sections were pre-hybridized with salmon
sperm DNA and then hybridized with fluorescein isothiocyanate-
labelled oligonucleotide probe for EBER1 and 2 (Novocastra,
Newcastle upon Tyne) at 37˚C overnight. After post-hybridization
washing with a combination of 150 mmol l–1 sodium chloride and
15 mmol l–1 sodium citrate (pH 7.0) at 50˚C, the specimens were
incubated with alkaline phosphatase-conjugated antibody to flu-
orescein isothiocyanate (Novocastra). Positive signals were visual-
ized after the addition of 5-bromo-4-chloro-3-indolylphosphate
and nitroblue tetrazolium. 
Clonality analysis of EBV terminal repeats 
Frozen tissues were minced on ice in buffer containing 15 mM
sodium chloride, 15 mM Tris-HCl and 1 mM EDTA, and
digested at 37˚C overnight with 0.025% proteinase K. Following
extraction with phenol/chloroform and ethanol precipitation,
DNA was resuspended in 10 mM Tris-HCl, 1 mM EDTA. Five
mg DNA was digested with BamHI and then separated on a 0.8%
agarose gel. The DNA was transferred to a nylon membrane and
then hybridized with a digoxigenin-labeled EBV terminal fragment
probe, an Xho-1 1.9 kb fragment (Raab-Traub and Flynn, 1986). 
mRNA preparation and RT-PCR 
mRNAs were extracted from frozen skin biopsy specimens or 
106 control cells using a Micro-FastTrackTM 2.0 kit (Invitrogen,
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Table 1 Oligonucleotides used in RT-PCR for EBV transcripts 
cDNA Oligos Oligonucleotide  Coordinated in B95.8 Annealing temperature Reference 
sequence (5¢-3¢)
EBNA1 Y3 TGGCGTGTGACGTGGTGTAA 48397–48416 60˚C Brooks et al, 1992 
Q GTGCGCTACCGGATGGCG 62440–62457 55˚C 
K CATTTCCAGGTCCTGTACCT 107986–107967 
probe AGAGAGTAGTCTCAGGGCAT 67544–67563 
EBNA2 H1 AAGCGCGGGTGCTTAGAAGG 48478–48459 55˚C Oudejans et al, 1995a 
Y2 ATTAGAGACCACTTTGAGCC 47902–47921 
probe CTGTCCCGTATACACAGGGC 54425–54406 
LMP1 primer GTGACTGGACTGGAGGAGCC 169341–169322 62˚C Tao et al, 1998 
primer GAGGGAGTCATCGTGGTGGTG 168718–168738 
probe AGCCCTCCTTGTCCTCTA 179325–169308 
BHRF1 Y2 ATTAGAGACCACTTTGAGCC 47902–47921 55˚C Oudejans et al, 1995a 
H2 GTCAAGGTTTCGTCTGTGTG 53830–63849 53˚C 
H3 TTCTCTTGCTGCTAGCTCCA 54480–54461 
probe CTGTCCCGTATACACAGGGC 54425–54406 
BCRF1 primer CGAAGGTTAGTGGTCACTCT 9681–9700 57˚C Miyazaki et al, 1993 
primer CACCTGGCTTTAATTGTCATG 10186–10166 
probe TACCTGGAGGAAGTCATGCC 9921–9940 922 Z-G Xu et al 
British Journal of Cancer (2001) 84(7), 920–925 © 2001 Cancer Research Campaign
California). Reverse transcription was performed using a cDNA
Cycle kit (Invitrogen). PCR amplification was done with an initial
denaturation at 95˚C for 5 min, followed by 40 cycles consisting of
95˚C for 1 min, an optimal annealing temperature for 45 s, 72˚C
for 1 min, and a final extension at 72˚C for 10 min. The RT-PCR
products were transferred to nylon membranes, and then
hybridized with biotin-labelled oligonucleotide probes as
described previously (Xu et al, 2000). Transcription of EBV-
encoded genes including the EBNA-1, EBNA-2, LMP-1, BHRF1
and BCRF1 genes was examined. The sequences of the primers,
the annealing temperatures for PCR amplifications and the
oligonucleotide probes for hybridization are described in Table 1. 
Immunostaining 
In order to detect EBV antigens, monoclonal antibodies (DAKO)
to LMP-1 (clone CS1-4), EBNA-2 (clone PE2) and ZEBRA (clone
BZLF1) were used. Before incubation with anti-EBNA-2 or anti-
ZEBRA antibody, deparaffinized tissue sections were boiled for
5 min in citrate buffer (0.1 mol l–1, pH 6.0). Incubation with the
antibodies was done at 4˚C overnight. For immunophenotyping of 
the infiltrating cells, monoclonal antibodies to CD2, 3, 4, 8, 16, 
30, 45RO and 57 (DAKO) and CD56 (Novocastra) were used. 
The tissue sections were reacted with biotin-labeled anti-mouse
immunoglobulins, followed by incubation with horseradish perox-
idase-labelled streptavidin. Colorimetric reaction was performed
by incubation with a substrate solution containing diaminobenzi-
dine and hydrogen peroxide. 
RESULTS 
Clinicopathologic findings 
The clinical features of six patients with a NK-cell phenotype (NK
1–6) and two patients with a T-cell phenotype (T1 and 2) are
summarized in Table 2. Histologically, tissue necrosis and
angiodestructive infiltrates were common in all patients at various
degrees. All six patients with a NK-cell phenotype represented
CD56 and cytoplasmic CD3 (CD3 e) without any T-cell-specific
antigens (Figure 1A) and positive signals for EBER (Figure 1B).
EBER+ cells ranged from 30–80% of the infiltrating cells.
Southern blot hybridization demonstrated non-rearranged T-cell
receptor genes (Figure 2). By contrast, rearranged bands of the 
T-cell receptor gene were detected in two patients (T1 and 2),
although a few CD56+ cells were observed in case T1 (data not
shown). These findings confirmed that the tumour cells in cases T1
and T2 were of T-cell lineage. 
DNA samples from five patients were subjected to clonality
analyses of EBV. The results showed a single hybridization band
B A
Figure 1 Infiltrating cells in the skin lesions expressing (A) CD56 (´ 600) and (B) EBER (´ 400) 
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Figure 2 Clonality analysis of a representative case of nasal-type, 
NK/T-cell lymphoma (NK-cell phenotype). Southern blot hybridization using a
digoxigenin-labelled Xho-1 probe (Raab-Traub and Flynn, 1986)
demonstrated a single band corresponding to EBV BamHI-digested
fragments containing the same number of EBV terminal repeats (*right) and
no rearrangement of TcR b gene (left). Pt = patient’s sample, B95-8 = an
EBV + cell line, (+) = EBV + lymphoma, (–) = EBV2lymphoma EB virus antigen expression by NK/T-cell lymphomas 923
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with a Xho-1 probe, indicating clonal proliferation of the
neoplastic cells infected with EBV containing the same number of
terminal repeats (Figure 2). 
Four years after onset, four patients (NK2, 3, 6 and T2) had died
because of progressive illness, and one patient (T1) died of a
complication unrelated to lymphoma. Among them, a patient with
NK-cell phenotype (NK2) had the most aggressive course, and
died 6 months after onset. 
Expression pattern of latency-associated EBV genes 
In order to determine the latency pattern of EBV infection in our
patients, we analysed the transcripts of the EBNA-1, EBNA-2 and
LMP-1 genes by RT-PCR. The EBNA-1 mRNA was found in all
patients and EBV-positive cell lines such as B95.8, Raji and
Jiyoye, whereas the EBNA-2 mRNA was absent in our patients
but was present in the cell lines. The EBNA-1 promoters used to
drive transcription were different between the patients and the cell
lines. The Cp/Wp, which generates a Y/U/K-spliced form, was
only used by cell lines (Table 3, Figure 3). By contrast, a down-
stream promoter, Qp, which produces a Q/U/K-initiated transcript,
was used in both the cell lines and our patients. Therefore, 
the EBNA-1 transcript was driven from the Qp in NK/T-cell
lymphomas without usage of the Cp/Wp. The LMP-1 mRNA was
detected in seven of eight patients and the EBV-positive cell lines. 
The expression of the BHRF1 gene, which has partial sequence
homology to the human bcl-2 proto-oncogene, was studied using
two different primer sets, Y2/H3 and H2/H3 for detection of
possible latent (Y2/HF-spliced) and lytic (H2/HF-spliced) tran-
scripts, respectively (Oudejans et al, 1995b). Both latent Y2/HF-
and lytic H2/HF-spliced transcripts of the BHRF1 gene were
detected in the EBV-positive cell lines, whereas only the latent
Table 2 Patients with cutaneous NK/T-cell lymphomas 
Case/age/sex Involved organs Immunophenotype TCRb EBV-TR Outcome 
NK1/70/M nose, skin cCD3+, CD56+, 30–, 45RO–, 8–/+, 4–/+ G Clonal Alive 
NK2/63/F nose, skin, LN cCD3+, CD56+, 2+, 57–, 16–, 30– G Clonal Dead 
NK3/16/M skin cCD3+, CD56+, 4–, 8–, 30– G ND Dead 
NK4/74/F skin cCD3+, CD56+, 30+, 4–, 8– ND Clonal Alive 
NK5/48/F skin, LN cCD3+, CD56+, 45RO+, 8–, 4– G Clonal Alive 
NK6/80/M skin cCD3+, CD56+, 4–, 8–, 30– G ND Dead 
T1/64/F skin, LN cCD3+, CD56–/+, 3–/+, 4+, 8+, 45RO+ R Clonal Deada
T2/36/F skin cCD3+, CD56–, 45RO+ R ND Dead 
NK = NK-cell lymphomas, T = T-cell lymphomas, LN = lymph node, TCR = T-cell receptor, EBV-TR = EBV terminal repeats, + = positive, G = germ, 
R = rearranged, ND = not done. aThe cause of death was unrelated to lymphoma.
Table 3 The expression patterns of EBV-encoded genes by NK/T-cell lymphomas 
Cases EBER by ISH EBV gene expression determined by RT-PCR EBV antigen expression by immunostaining 
EBNA1 EBNA2 LMP-1 BHRF1 BCRF1 LMP-1 EBNA ZEBRA 
YUK QUK Y2/H3 H2/H3 (vIL-10) 
NK1 + – + – + – – – – – – 
NK2 + – + – + + – + – – – 
NK3 + – + – + – – +/– – – – 
NK4 + – + – + – – – – – – 
NK5 + – +/– – – – – – – ND ND 
NK6 + – + – + – – – ND ND ND 
T1 + – + – + – – – – – – 
T2 + – + – + – – – – – – 
Molt ND – – – – – – – – – – 
B95.8 + + + + + + + + + + + 
Raji ND + + + + + + + + + + 
Jiyoye ND + + + + + +/– + + + + 
EBER = EBV2encoded small nuclear RNA, ISH = in situ hybridization, + = positive; +/– = weakly positive, – = negative, ND = not done.
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Figure 3 Transcripts of EBV genes in NK/T-cell lymphoma. Schematic
drawings indicate the complementary sites of the primer sets. The Q/U/K-
spliced EBNA-1 and LMP-1 transcripts are detected in all EBV+ NK/T-cell
lymphomas, but neither Y3/U/K-spliced EBNA-1 nor EBNA-2 transcript is
negative. Among the patients’ samples, the latent Y2/H3(HF)-spliced BHRF1
transcript is positive in one case (NK2), and the BCRF1 transcript is present
in two cases (NK2 and 3). NK = NK-cell lymphoma, T = T-cell lymphoma924 Z-G Xu et al 
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Y2/HF-spliced transcript was detected in one (NK2) of eight
patients with NK/T-cell lymphoma. 
The BCRF1 gene, which encodes viral IL-10, was transcribed in
all EBV-positive cell lines and two patients (NK2 and 3). The
patient, NK2, who died of the most aggressive course of the
illness, expressed both the BHRF1 (bcl-2 homologue) and BCRF1
(viral IL-10) transcripts. 
EBV antigen expression 
The EBNA-2 and ZEBRA, an ‘immediate-early’ transcriptional act-
ivator was detected in the paraffin-embedded cell pellets of B95.8,
Raji and Jiyoye cells, although the percentages of the positive cells
varied in the cell lines (Figure 4). Neither EBNA-2- nor ZEBRA-
positive cells were detected in the lesional tissue sections from our
patients. With paraffin-embedded tissue sections, LMP-1 antigens were
strongly expressed by the EBV-positive cell lines, but no LMP-1
antigens were detected in the biopsy specimens from the patients. 
DISCUSSION 
Our study demonstrats that in addition to EBER, both the EBNA-1
and LMP-1 genes are transcribed in vivo in patients with EBV-
associated NK/T-cell lymphomas, without any EBNA-2 gene
transcript. This finding was further confirmed by the usage of
promoters for the EBNA-1 gene in the patients: the Qp promoter
was used in the NK/T-cell lymphomas, and both the Qp and
Cp/Wp were used in the EBV-positive cell lines. When the Qp
promoter is used, the Q/U/K-spliced EBNA-1 mRNA is generated,
but the other latent genes, such as EBNA-2 and EBNA-3, cannot
be transcribed because the Cp/Wp promoters are silent. These
results indicate that the nasal-type, extranodal NK/T-cell lympho-
mas expressed viral antigens of EBNA-1 and LMP-1 in the latency
II pattern. Unlike the latency III pattern observed in EBV-related
lymphoproliferative disorders in patients with immunodeficiency
(Hamilton-Dutoit et al, 1993), NK/T-cell lymphomas may mini-
mize the expression of the latency-associated viral antigens which
might be targeted by host immune system. 
EBNA-1 is constantly expressed by EBV-infected cells in any
latency pattern, but the host’s immune response never occurs
against the molecules (Levitskaya et al, 1995). LMP-1 acts as a
direct oncogene to transform epithelial cells morphologically
(Fahraeus et al, 1990) and prevent B-lymphoma cells from under-
going apoptosis by up-regulating the expression of cellular bcl-2
(Henderson et al, 1991). We could not detect LMP-1 antigens by
immunostaining despite the presence of LMP-1 gene transcripts
by RT-PCR. This discrepancy may be because RT-PCR is more
sensitive than immunostaining using paraffin-embedded tissue
sections. 
The EBV BHRF1 gene encodes a protein which has sequence
homology to cellular bcl-2, and this viral bcl-2 homologue protects
cells from apoptosis (Henderson et al, 1993). High levels of the
BHRF1 transcript are expressed in the lytic cycle, but differently
spliced BHRF1 transcript was found during latency, although 
at much lower levels (Oudejans et al, 1995b). In our series, the
latent (Y2/HF-spliced) transcript was present in one case (NK2),
whereas no lytic (H2/HF-spliced) transcript was detected in the
patients’ samples. The BCRF1 gene encodes viral IL-10 which has
more than 70% amino acid identity with human IL-10 (Moore 
et al, 1990). Human and viral IL-10 share several biological func-
tions such as inhibition of interferon-g secretion and suppression
of T-cell proliferation (Hsu et al, 1990). It has been postulated that
the production of human IL-10 correlates with poor prognosis in
non-Hodgkin’s lymphoma (Blay et al, 1993). In our series, the
BCRF1 gene was transcribed in two patients with cutaneous NK-
cell lymphomas (NK2 and 3) who died after two years because of
progression of the illness. In particular, a patient, NK2, with simul-
taneous expression of both viral IL-10 and viral bcl-2 homologue,
did have an aggressive clinical course. 
The BCRF1 gene encoding viral IL-10 was thought to be tran-
scribed only during a lytic phase of EBV replication (Hudson et al,
1985), but was recently found to be expressed very early during 
B-cell infection (Miyazaki et al, 1993; Zeidler et al, 1997).
Although the mechanism of the BCRF1 gene expression has been
a controversial issue, we could not rule out the possibility that a
small number of the neoplastic cells changed from the latent to the
A B
C D
Figure 4 Immunostaining of the LMP-1 and ZEBRA antigens in paraffin-embedded tissue and cell preparations from NK/T-cell lymphomas and an EBV+
lymphoblastic cell line, B95.8, respectively. Neither (A) LMP-1 nor (C) ZEBRA is present in the NK/T cell lymphoma, but both antigens (B and D, respectively)
are positive in B95.8 EB virus antigen expression by NK/T-cell lymphomas 925
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lytic cycle (Miller, 1990). Alternatively, bystander or reactive cells
with lytic EBV infection might coexist in the lesions. 
In conclusion, the latency II pattern of viral gene transcripts in
the nasal-type, NK/T cell lymphomas (EBER+, EBNA1+, LMP-1+,
EBNA2–) is distinct from that identified in B-cell system, and
consistent with that identified in nasopharyngeal carcinomas.
Furthermore, the expression of viral IL-10 and bcl-2 homologue
might be responsible for tumour progression by interference with
the host immune system and apoptosis, respectively. 
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